Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ADX-097 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Open Label: ADX-097 | OTHER | Participants will be administered ADX-097 weekly once |
| Name | Type | Description |
|---|---|---|
| ADX-097 | DRUG | Subcutaneous Infusions |
Key Inclusion Criteria: All participants 1. Male or female participants aged ≥16 years. 2. uPCR ≥0.5 g/g (from the average of 3 first morning voids \[FMVs\]). 3. Screening eGFR ≥30 mL/min/1.73m2 calculated by the Chronic Kidney Disease Epidemiology Collaboration creatinine equation (CKD-EPI GFR). ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 12 | PHASE3 | Zigakibart, Atrasentan, Iptacopan |
| Vera Therapeutics, Inc. Class A | VERA | 4 | PHASE3 | Atacicept |
| Biogen Inc. | BIIB | 1 | PHASE3 | Felzartamab |
| AstraZeneca PLC | AZN | 2 | PHASE3 | Ravulizumab |
| Vertex Pharmaceuticals Incorporated | VRTX | 3 | PHASE3 | Povetacicept |
| Biohaven Ltd. | BHVN | 2 | PHASE3 | BHV-1400 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Sefaxersen |
| Travere Therapeutics, Inc. | TVTX | 1 | PHASE2 | Sparsentan |
| argenx SE Sponsored ADR | ARGX | 1 | PHASE2 | ARGX-121 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-097 |
| Jade Biosciences, Inc. | JBIO | 1 | PHASE2 | JADE101 |
ADX-097 is an investigational small molecule being developed for the treatment of IgA Nephropathy, a kidney disease. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
ADX-097 targets C3d, a fragment of the complement protein C3. By targeting C3d, the drug aims to modulate the complement system, which is involved in the pathogenesis of IgA Nephropathy and other complement-mediated kidney diseases.
ADX-097 is being developed by Q32 Bio Inc., a biopharmaceutical company. Q32 Bio is publicly traded on the Nasdaq under the ticker symbol QTTB.
ADX-097 is in Phase 2 clinical development. It is currently being evaluated in a Phase 2 study that is recruiting participants. The drug is investigational and has not been approved by the FDA or other regulatory agencies.
ADX-097 is being studied in a Phase 2 clinical trial with the identifier NCT06419205. This trial is evaluating the safety, pharmacodynamics, pharmacokinetics, and clinical activity of ADX-097 in participants with IgA Nephropathy, Lupus Nephritis, or C3 Glomerulopathy. The study is recruiting up to 30 participants in the United States and Brazil.